Frequently Asked Questions

Prevena Health is a health technology company building a continuous molecular intelligence platform. The platform is designed to detect subtle biological signals through non-invasive wearable sensing, multiplexed assay cartridges, and a clinician-connected intelligence layer. Prevena Health's goal is to support earlier awareness of disease-related molecular changes. Learn more on our homepage.

Continuous molecular intelligence refers to the ongoing, automated measurement and analysis of molecular biomarkers over time, rather than relying on single-point-in-time laboratory tests. Prevena Health's platform is designed to sample interstitial fluid continuously, quantify relevant analytes, and surface trends that may indicate early biological changes.

No. Prevena Health's platform is currently in development and is not commercially available. The company is conducting research and development to validate its technology and biomarker approach. Information on this website is provided for informational purposes only.

No. Prevena Health's platform has not been cleared, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. The platform is in the research and development phase, and regulatory submissions have not yet been made.

Prevena Health is a U.S.-based health technology company. For inquiries, you can reach the team at contact@prevenahealth.com.

The Prevena Health platform consists of three integrated components: a skin-worn wearable sensor that continuously samples interstitial fluid, a multiplexed assay cartridge that quantifies multiple biomarkers simultaneously, and a mobile app with an intelligence layer that analyzes trends over time. Together, these components are designed to provide longitudinal molecular data to clinicians and researchers. See the Platform overview for more details.

The wearable sensor is a skin-worn device designed to continuously sample interstitial fluid through minimally invasive microneedle technology. It is intended to be comfortable for extended wear and to provide a steady stream of molecular data without requiring traditional blood draws.

The assay cartridge is a multiplexed consumable component that quantifies multiple biomarkers from a single interstitial fluid sample. It is designed to detect protein, nucleic acid, and metabolic analytes associated with various disease areas using advanced immunoassay and molecular detection technologies.

The mobile app receives biomarker data from the wearable sensor and assay cartridge, then presents longitudinal trends to users and their clinicians. The intelligence layer applies algorithmic analysis to identify meaningful changes in biomarker trajectories, helping to surface signals that may warrant further clinical evaluation.

Interstitial fluid (ISF) is the fluid that surrounds cells in body tissues. Research has shown that many clinically relevant biomarkers present in blood are also detectable in ISF. Sensing ISF through microneedle-based wearable technology may offer a less invasive alternative to repeated blood draws for molecular monitoring.

Prevena Health is investigating biomarkers associated with several major disease areas, including cancer, cardiac disease, stroke, Alzheimer's disease, and neurological injury. The platform is designed to be extensible across multiple conditions where early molecular signals may precede clinical symptoms.

The platform is being developed to track a range of circulating biomarkers, including high-sensitivity troponin, NT-proBNP, D-dimer, C-reactive protein (CRP), circulating tumor DNA (ctDNA), PSA, neurofilament light chain (NfL), GFAP, phosphorylated tau (p-tau), and others. The specific panel depends on the disease area under investigation.

Traditional blood tests provide a single snapshot of biomarker levels at one moment in time. Continuous molecular monitoring, as Prevena Health is developing, aims to track biomarker trajectories over days, weeks, and months. This longitudinal approach may reveal trends, rate-of-change patterns, and subtle shifts that a single test could miss.

No. Prevena Health's platform is not a diagnostic device and is not intended to diagnose, treat, cure, or prevent any disease. It is being designed as a molecular surveillance tool that surfaces biomarker signals and trends for review by qualified healthcare professionals. Any clinical decisions should be made by a licensed clinician.

Longitudinal molecular monitoring is the practice of measuring and tracking molecular biomarkers repeatedly over an extended period. By observing how biomarker levels change over time, clinicians and researchers may identify trends that indicate emerging biological changes earlier than periodic single-point testing.

Prevena Health is committed to protecting personal and health-related data through encryption, access controls, and privacy-by-design principles. The platform is being developed with data security as a foundational requirement. For details, see our Privacy Policy.

Prevena Health is designing its platform and data handling practices with HIPAA compliance requirements in mind. As the platform is still in development, full compliance measures are being built into the architecture from the ground up to ensure readiness for clinical deployment.

No. Prevena Health is not an emergency service. The platform and any future alerting features are not substitutes for calling 911 or seeking immediate medical care. If you are experiencing a medical emergency, call emergency services immediately.

Prevena Health's platform is designed to present biomarker data and trends to qualified healthcare professionals, including clinicians and researchers. The platform is intended to support — not replace — clinical judgment. Data interpretation and any resulting medical decisions are the responsibility of licensed healthcare providers.

Prevena Health is pursuing rigorous clinical validation of its sensing technology, assay performance, and biomarker correlations. The company is committed to evidence-based development and plans to publish research findings and seek appropriate regulatory pathways as the platform matures.

Prevena Health welcomes collaboration with clinicians, researchers, and academic institutions interested in continuous molecular surveillance. To explore partnership opportunities, please contact partners@prevenahealth.com or visit the Partners section of our website.

Prevena Health is open to conversations with aligned investors who share the company's vision for proactive, molecular-level health monitoring. For investment inquiries, please reach out to contact@prevenahealth.com.

Prevena Health is designing its platform with health system integration in mind, including compatibility with electronic health record (EHR) systems and clinical workflows. As the platform advances through development, the company plans to work with health system partners to ensure seamless integration.